Clinical Trial Update: Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated dasatinib in patients with chronic myeloid leukemia that is resistant or intolerant to imatinib; results from the trial were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Leukemia

Drugs mentioned

• Sprycel (dasatinib) (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2010-02-24